Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A Safety and Efficacy Extension Study of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (DreaMS)
Glatiramer acetate inhibits degradation of collagen II by suppressing the activity of interferon regulatory factor-1.
Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia.
Getting a Handle on Lymphopenia With Tecfidera
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis.
Dimethyl fumarate (BG-12, Tecfidera) - NICE says yes in draft final guidance
Effect of disease duration on personality type in multiple sclerosis patients and healthy individual.
Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages.
Beneficial actions of the anti-inflammatory dimethyl fumarate in glioblastomas.
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a.
Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study.
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.
Emerging oral agents for multiple sclerosis.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
Biogen Idec reports death of patient on its MS pill
Interferon beta-1b therapy in chronic viral dilated cardiomyopathy--is there a role for specific therapy?
Epigenetic Modulation of Human Induced Pluripotent Stem Cell Differentiation to Oligodendrocytes.
Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.
Genpharm and Genzyme Aubagio ® agreement for the MENA region
Ethnicity and prevalence of multiple sclerosis in east London.
EU regulator warns on possible MS drugs side effects
Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
The impact of multiple sclerosis relapse treatment on migration of effector T cells - Preliminary study.

Pages